MedTrace Logo

A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

NCT05868876 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2025-03-03

No results posted yet for this study

Summary

A Phase Ia/Ib open label，clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors

Conditions

  • Advanced Malignant Tumors

Interventions

DRUG

AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion

AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.

Sponsors & Collaborators

Principal Investigators

  • Jihui Hao, Doctor · Tianjin Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-29
Primary Completion
2025-11-30
Completion
2026-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05868876 on ClinicalTrials.gov